Health & Fitness
Edison Expands Oncology Sector Presence with Launch of Research Coverage on Sunesis Pharmaceuticals
LONDON--([ BUSINESS WIRE ])--Edison Investment Research, a UK-based independent equity research firm, announces the initiation of research coverage on Sunesis Pharmaceuticals, Inc (NASDAQ:SNSS), a US biopharmaceutical company.
Edison has today published a comprehensive report examining the investment merits of Sunesis focusing on the potential of its lead programme, vosaroxin, for the treatment of acute myeloid leukemia (AML). Edison considers that the investment case for Sunesis critically depends on the outcome of a pivotal 450-patient Phase III clinical trial of vosaroxin in relapsed/refractory AML. This study, known by the acronym VALOR, has an innovative, adaptive design that allows for a one-time sample size adjustment based on the outcome of an interim analysis, due in mid-2012. The final outcome of the study should become known in 2013.
For the full report see: [ http://www.edisoninvestmentresearch.co.uk/research/company/sunesis-pharmaceuticals ]
The launch of coverage on Sunesis is part of a program of research coverage initiations on biotech companies worldwide. Edison covers over 65 biotech companies located in Europe, North America and Australia. Its biotech research team has a particular focus on small- to mid-cap companies active in the area of oncology with 14 companies now under active coverage in this space.1 All reports published by Edison are available to download, free of charge, from the website [ www.edisoninvestmentresearch.co.uk ].
Edison has pioneered a scientific detail-orientated approach to analyzing companies in the biotech sector that aims to inform investors while providing a realistic assessment of the competitive strengths and threats to key drug development programs. Reports are written in a concise and non-promotional manner. All facts are carefully sourced and the analysis is underpinned by comprehensive and rigorous financial models. Edisona�s reports provide an overall company valuation without any specific stock recommendation or target price.
About Edison Investment Research
Edison Investment Research is a leading international investment research company. The team of more than 75 includes over 40 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 350 companies across every sector and its research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London and Sydney and is authorised and regulated by the UK Financial Services Authority ([ www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584 ]). Edison is not a US investment adviser or broker-dealer and does not provide investment advice. Edisona�s reports are not solicitations to buy or sell any securities.
Notes:
1 Other cancer-focused companies under coverage by Edison include: 4SC AG (Frankfurt: VSC), Agennix Inc (Frankfurt: AGX), Algeta ASA (OSE: ALGETA), Astex (NASDAQ: ASTX), Epicept (NASDAQ OMX Stockholm: EPCT), Bionomics Limited (ASX: BNO), Circadian Technologies Limited (ASX: CIR), Hybrigenics (NYSE Alternext: ALHYG), Oncolytics Biotech Inc (TSX: ONC, NASDAQ: ONCY), Synta Pharmaceuticals, Corp (NASDAQ: SNTA), Topotarget A/S (NASDAQ OMX: TOPO), Wilex AG (Frankfurt: WL6) and YM Biosciences Inc (TSX: YM/NYSE Amex: YMI). Edison has also published ad hoc QuickView reports on other cancer-focused companies including: Bavarian Nordic (NASDAQ OMX: BAVA), Clavis Pharma ASA (OSE: CLAVIS), Innate Pharma (Paris: IPH), Micromet (NASDAQ: MITI), MolMed S.p.A.(Milan: MLM), Photocure ASA (OSE: PHO), Transgene (Paris: TNG), Zeltia SA (Madrid: ZEL) and Ziopharm Oncology (NASDAQ: ZIOP).
